Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

First Posted Date
2005-07-08
Last Posted Date
2015-03-18
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
75
Registration Number
NCT00117689
Locations
🇺🇸

University of Colorado Hospital and Health Sciences Center, Denver, Colorado, United States

🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Mount Sinai Medical Center, New York, New York, United States

and more 13 locations

Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

Phase 2
Terminated
Conditions
Graft vs Host Disease
First Posted Date
2005-07-08
Last Posted Date
2009-06-18
Lead Sponsor
Technische Universität Dresden
Target Recruit Count
24
Registration Number
NCT00117702
Locations
🇩🇪

Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus, Dresden, Germany

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

First Posted Date
2005-06-08
Last Posted Date
2011-08-11
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
501
Registration Number
NCT00113269

Campath-1H + FK506 and Methylprednisolone for GVHD

First Posted Date
2005-05-04
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
34
Registration Number
NCT00109993
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

🇺🇸

Mt. Sinai Medical Center, New York, New York, United States

🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 3 locations

A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
Drug: CP-690,550
Drug: tacrolimus
First Posted Date
2005-03-29
Last Posted Date
2013-03-12
Lead Sponsor
Pfizer
Target Recruit Count
61
Registration Number
NCT00106639
Locations
🇺🇸

Pfizer Investigational Site, Milwaukee, Wisconsin, United States

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

First Posted Date
2005-03-24
Last Posted Date
2010-11-23
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
131
Registration Number
NCT00106392

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

First Posted Date
2005-03-11
Last Posted Date
2012-12-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
27
Registration Number
NCT00105235
Locations
🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 6 locations

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

First Posted Date
2005-03-04
Last Posted Date
2016-12-15
Lead Sponsor
Yale University
Target Recruit Count
20
Registration Number
NCT00104975
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

First Posted Date
2005-03-04
Last Posted Date
2019-10-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
210
Registration Number
NCT00105001
Locations
🇩🇰

Rigshospitalet University Hospital, Copenhagen, Denmark

🇺🇸

Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

🇩🇪

Medizinische Univ Klinik Koln, Koln, Germany

and more 8 locations

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

First Posted Date
2004-11-09
Last Posted Date
2010-05-13
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00096096
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy